Aurinia to Webcast at Upcoming Investor Conferences
September 05 2017 - 12:05PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”
or the “Company”) plans to present at three upcoming investor
conferences where Aurinia management will provide an overview of
the Company. The conferences will be webcast live and will be
available in the Investor Relations section of the Company's
website at www.auriniapharma.com.
Monday, September 11, 2017, Aurinia will present at the Rodman
& Renshaw 19th Annual Global Investment Conference in New York
City at 2:35pm ET
Tuesday, September 26, 2017, Aurinia will present at the Cantor
Fitzgerald 3rd Annual Healthcare Conference in New York City at
10:55am ET
Wednesday, September 27, 2017, Aurinia will present at the
LEERINK Partners Roundtable Series: Rare Disease &
Immuno-Oncology in New York City at 8:00am ET
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The company
is currently developing voclosporin, an investigational drug, for
the treatment of lupus nephritis (LN). The company is headquartered
in Victoria, BC and focuses its development efforts globally.
www.auriniapharma.com
Forward Looking StatementsThis press release contains
forward-looking statements, which are generally statements that are
not historical facts.. Words such as "plans," "intends,"
“may,” "will," "believe," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Aurinia’s current expectations.
Forward-looking statements involve risks and uncertainties.
Aurinia’s actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties. These and
other risk factors are discussed under "Risk Factors" and elsewhere
in Aurinia’s Annual Information Form for the year ended December
31, 2016 filed with Canadian securities authorities and available
at www.sedar.com and on Form 40-F with the U.S. Securities Exchange
Commission and available at www.sec.gov, each as updated by
subsequent filings, including filings on Form 6-K. Aurinia
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Aurinia's expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based, except as
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170905005991/en/
Aurinia Pharmaceuticals Inc.Investors:Celia
EconomidesVice President, Public
Affairsceconomides@auriniapharma.comorMedia:Chris
HippolyteChristopher.Hippolyte@inventivhealth.com